(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide...
Stats | |
---|---|
Šios dienos apimtis | 3.21M |
Vidutinė apimtis | 1.65M |
Rinkos kapitalizacija | 10.18B |
EPS | $-0.550 ( Q3 | 2024-05-08 ) |
Kita pelno data | ( $0.460 ) 2024-09-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-8.68 (Sector) 49.64 (Industry) 35.32 |
ATR14 | $0.0240 (0.04%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-04 | Hopson Ricky | Sell | 1 401 | Common Stock |
2024-03-15 | Gunther Scott | Sell | 387 | Common Stock |
2024-01-25 | Kreuzburg Christa | Sell | 523 | Common Stock |
2024-01-16 | Hatzfeld Michael | Buy | 6 071 | Common Stock |
2024-01-16 | Hatzfeld Michael | Buy | 3 981 | Options to purchase Common Stock |
INSIDER POWER |
---|
69.89 |
Last 95 transactions |
Buy: 316 064 | Sell: 55 780 |
Tūris Koreliacija
Catalent Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
CB | 0.891 |
SPLP-PA | 0.88 |
SBXC | 0.877 |
GEV | 0.865 |
KMPR | 0.864 |
CTRI | 0.862 |
NLY-PI | 0.861 |
OSG | 0.859 |
IHTA | 0.857 |
COR | 0.855 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
BBAI-WT | -0.939 |
RTO | -0.921 |
OAK-PB | -0.918 |
OAK-PA | -0.916 |
SRFM | -0.907 |
CCG | -0.906 |
CRI | -0.904 |
AIZN | -0.902 |
BYON | -0.898 |
QBTS-WT | -0.889 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Catalent Inc Koreliacija - Valiuta/Žaliavos
Catalent Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $4.28B |
Bruto pelnas: | $1.06B (24.79 %) |
EPS: | $-1.280 |
FY | 2023 |
Pajamos: | $4.28B |
Bruto pelnas: | $1.06B (24.79 %) |
EPS: | $-1.280 |
FY | 2022 |
Pajamos: | $4.83B |
Bruto pelnas: | $1.64B (33.97 %) |
EPS: | $2.74 |
FY | 2021 |
Pajamos: | $4.00B |
Bruto pelnas: | $1.35B (33.82 %) |
EPS: | $3.15 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Catalent Inc
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.